Jennifer Power, TFC Therapeutics CEO

ARCH's lat­est biotech, tar­get­ing can­cer re­cur­rence, emerges from Co­lum­bia pro­fes­sor who worked on Biden's moon­shot

TFC Ther­a­peu­tics, a new ARCH Ven­ture Part­ners biotech, on Thurs­day un­veiled a mis­sion to thwart the re­turn of can­cer and its spread to oth­er parts of the body with new bi­o­log­ics.

The ear­ly-stage New York start­up builds off four decades of can­cer re­search out of Co­lum­bia Uni­ver­si­ty med­ical pro­fes­sor Azra Raza.

TFC has the ex­clu­sive li­cense to de­vel­op a drug dis­cov­ery plat­form tar­get­ing tu­mor macrophage hy­brid, or TMH, cells based on work out of Raza’s lab along­side prin­ci­pal sci­en­tist and as­sis­tant pro­fes­sor Ab­dul­lah Ali. Raza di­rects the MDS Cen­ter at Co­lum­bia and has led re­search on myelodys­plas­tic syn­drome, var­i­ous leukemias and oth­er can­cers across a ca­reer span­ning Rush Uni­ver­si­ty, the Uni­ver­si­ty of Mass­a­chu­setts and else­where be­fore mov­ing to her cur­rent base in 2010.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.